Short- and long-term follow-up and additional benefits in a sickle cell disease patient experienced severe crizanlizumab infusion-related vaso-occlusive crisis: A case report
Sickle cell disease is an autosomal recessive disorder characterized by the presence of sickle hemoglobin that leads to chronic hemolysis and vaso-occlusive crisis. After decades of limited therapy options, crizanlizumab is a humanized monoclonal antibody approved by the Food and Drug Administration...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-11-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2022.1048571/full |
| _version_ | 1811214678004596736 |
|---|---|
| author | Awni Alshurafa Mohamed A. Yassin |
| author_facet | Awni Alshurafa Mohamed A. Yassin |
| author_sort | Awni Alshurafa |
| collection | DOAJ |
| description | Sickle cell disease is an autosomal recessive disorder characterized by the presence of sickle hemoglobin that leads to chronic hemolysis and vaso-occlusive crisis. After decades of limited therapy options, crizanlizumab is a humanized monoclonal antibody approved by the Food and Drug Administration (FDA) in 2019 for sickle cell-related pain crises for patients 16 years of age and above. Although rare, infusion-related reactions, including painful crises, occurred in 3% as per the package insert. However, the data on how to deal with such reactions and about further treatment outcomes are limited as most patients stopped crizanlizumab after the reaction. Herein, we report the good outcome of 13 doses of crizanlizumab in a 19-year-old female patient with sickle cell disease on hydroxyurea, despite experiencing a severe infusion-related painful crisis during the second infusion. Additional benefits of crizanlizumab, in this case, were preventing new episodes of acute chest syndrome, quitting chronic narcotics use, and a remarkable improvement in quality of life and overall performance. |
| first_indexed | 2024-04-12T06:07:54Z |
| format | Article |
| id | doaj.art-02308d2e9fe446a7b21fdf3bbc79cd9c |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-04-12T06:07:54Z |
| publishDate | 2022-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-02308d2e9fe446a7b21fdf3bbc79cd9c2022-12-22T03:44:47ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2022-11-01910.3389/fmed.2022.10485711048571Short- and long-term follow-up and additional benefits in a sickle cell disease patient experienced severe crizanlizumab infusion-related vaso-occlusive crisis: A case reportAwni AlshurafaMohamed A. YassinSickle cell disease is an autosomal recessive disorder characterized by the presence of sickle hemoglobin that leads to chronic hemolysis and vaso-occlusive crisis. After decades of limited therapy options, crizanlizumab is a humanized monoclonal antibody approved by the Food and Drug Administration (FDA) in 2019 for sickle cell-related pain crises for patients 16 years of age and above. Although rare, infusion-related reactions, including painful crises, occurred in 3% as per the package insert. However, the data on how to deal with such reactions and about further treatment outcomes are limited as most patients stopped crizanlizumab after the reaction. Herein, we report the good outcome of 13 doses of crizanlizumab in a 19-year-old female patient with sickle cell disease on hydroxyurea, despite experiencing a severe infusion-related painful crisis during the second infusion. Additional benefits of crizanlizumab, in this case, were preventing new episodes of acute chest syndrome, quitting chronic narcotics use, and a remarkable improvement in quality of life and overall performance.https://www.frontiersin.org/articles/10.3389/fmed.2022.1048571/fullsickle cell diseasecrizanlizumabvaso-occlusive crisishemolytic anemiainfusion-related reactions |
| spellingShingle | Awni Alshurafa Mohamed A. Yassin Short- and long-term follow-up and additional benefits in a sickle cell disease patient experienced severe crizanlizumab infusion-related vaso-occlusive crisis: A case report Frontiers in Medicine sickle cell disease crizanlizumab vaso-occlusive crisis hemolytic anemia infusion-related reactions |
| title | Short- and long-term follow-up and additional benefits in a sickle cell disease patient experienced severe crizanlizumab infusion-related vaso-occlusive crisis: A case report |
| title_full | Short- and long-term follow-up and additional benefits in a sickle cell disease patient experienced severe crizanlizumab infusion-related vaso-occlusive crisis: A case report |
| title_fullStr | Short- and long-term follow-up and additional benefits in a sickle cell disease patient experienced severe crizanlizumab infusion-related vaso-occlusive crisis: A case report |
| title_full_unstemmed | Short- and long-term follow-up and additional benefits in a sickle cell disease patient experienced severe crizanlizumab infusion-related vaso-occlusive crisis: A case report |
| title_short | Short- and long-term follow-up and additional benefits in a sickle cell disease patient experienced severe crizanlizumab infusion-related vaso-occlusive crisis: A case report |
| title_sort | short and long term follow up and additional benefits in a sickle cell disease patient experienced severe crizanlizumab infusion related vaso occlusive crisis a case report |
| topic | sickle cell disease crizanlizumab vaso-occlusive crisis hemolytic anemia infusion-related reactions |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2022.1048571/full |
| work_keys_str_mv | AT awnialshurafa shortandlongtermfollowupandadditionalbenefitsinasicklecelldiseasepatientexperiencedseverecrizanlizumabinfusionrelatedvasoocclusivecrisisacasereport AT mohamedayassin shortandlongtermfollowupandadditionalbenefitsinasicklecelldiseasepatientexperiencedseverecrizanlizumabinfusionrelatedvasoocclusivecrisisacasereport |